Kolinpharma S.p.A.

BIT:KIP Stock Report

Market Cap: €15.9m

Kolinpharma Past Earnings Performance

Past criteria checks 2/6

Kolinpharma has been growing earnings at an average annual rate of 24.9%, while the Personal Products industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 16.1% per year. Kolinpharma's return on equity is 4.1%, and it has net margins of 2.2%.

Key information

24.9%

Earnings growth rate

23.3%

EPS growth rate

Personal Products Industry Growth13.6%
Revenue growth rate16.1%
Return on equity4.1%
Net Margin2.2%
Last Earnings Update31 Dec 2022

Recent past performance updates

Recent updates

Kolinpharma (BIT:KIP) Is Looking To Continue Growing Its Returns On Capital

Jun 17
Kolinpharma (BIT:KIP) Is Looking To Continue Growing Its Returns On Capital

What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?

Dec 01
What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?

An Intrinsic Calculation For Kolinpharma S.p.A. (BIT:KIP) Suggests It's 46% Undervalued

Aug 25
An Intrinsic Calculation For Kolinpharma S.p.A. (BIT:KIP) Suggests It's 46% Undervalued

We Think Kolinpharma (BIT:KIP) Can Stay On Top Of Its Debt

Jun 08
We Think Kolinpharma (BIT:KIP) Can Stay On Top Of Its Debt

Do Kolinpharma's (BIT:KIP) Earnings Warrant Your Attention?

May 21
Do Kolinpharma's (BIT:KIP) Earnings Warrant Your Attention?

Is There An Opportunity With Kolinpharma S.p.A.'s (BIT:KIP) 35% Undervaluation?

May 03
Is There An Opportunity With Kolinpharma S.p.A.'s (BIT:KIP) 35% Undervaluation?

Some Shareholders Feeling Restless Over Kolinpharma S.p.A.'s (BIT:KIP) P/E Ratio

Apr 13
Some Shareholders Feeling Restless Over Kolinpharma S.p.A.'s (BIT:KIP) P/E Ratio

What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?

Feb 20
What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?

Is Weakness In Kolinpharma S.p.A. (BIT:KIP) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Dec 28
Is Weakness In Kolinpharma S.p.A. (BIT:KIP) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

These 4 Measures Indicate That Kolinpharma (BIT:KIP) Is Using Debt Reasonably Well

Nov 22
These 4 Measures Indicate That Kolinpharma (BIT:KIP) Is Using Debt Reasonably Well

Revenue & Expenses Breakdown

How Kolinpharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BIT:KIP Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2216050
30 Sep 2214050
30 Jun 2213050
31 Mar 2213050
31 Dec 2113150
30 Sep 2113140
30 Jun 2113140
31 Mar 2111130
31 Dec 2010130
30 Sep 209130
30 Jun 209130
31 Mar 2010130
31 Dec 1910130
30 Sep 1910030
30 Jun 199020
31 Mar 199020
31 Dec 189020
30 Sep 188000
30 Jun 187010
31 Mar 186010
31 Dec 175010
31 Dec 164000
31 Dec 152-110

Quality Earnings: KIP has high quality earnings.

Growing Profit Margin: KIP's current net profit margins (2.2%) are lower than last year (5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: KIP has become profitable over the past 5 years, growing earnings by 24.9% per year.

Accelerating Growth: KIP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: KIP had negative earnings growth (-46.3%) over the past year, making it difficult to compare to the Personal Products industry average (-25.1%).

Return on Equity

High ROE: KIP's Return on Equity (4.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/11/01 09:39
End of Day Share Price 2023/09/27 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kolinpharma S.p.A. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luigi TardellaEnVent Capital Markets Limited
Luisa PrimiIR Top Consulting S.r.l.